YUBO INTERNATIONAL BIOTECH LIMITED (YBGJ)

Every figure this model derived for YBGJ, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2022-12-31
cash 11,989 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 583,098 AssetsCurrent 2026-06-30
current liabilities 3,327,598 LiabilitiesCurrent 2026-06-30
equity -2,622,591 StockholdersEquity 2026-06-30
interest expense 0 InterestPaidNet 2026-06-30
ocf -727,992 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 12,353 Revenues 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up YBGJ on one particular measure came for.

RatioValue
current ratio0.18
current ratio reported0.18
dilution pct16.56
growth cv1.8
revenue growth-68727.78
revenue growth per share-58979.14
rule of 40-77824.64
sbc pct revenue0.0

What to be careful about

What this model itself distrusts about YBGJ's figures. Written by the derivation as it ran, not added afterwards.